

THE UNITED STATES PATENT AND TRADEMARK OFFICE

Application of: Hiroyuki FUJITA

Serial No.: 09/663,709

September 18, 2000

ANGIOTENSIN CONVERTING ENZYME INHIBITOR

INFORMATION DISCLOSURE STATEMENT PURSUANT TO 37 CFR 1.97(b)

Commissioner for Patents Washington, D.C. 20231

September 27, 2001

Sir:

Filed:

For:

The attention of the Patent and Trademark Office is hereby directed to the documents listed on the attached Form PTO-1449. One copy of each of these documents is attached.

These documents were cited in a Search Report for a corresponding European application. A copy of the Search Report also is enclosed.

No fee or certification is required in connection with this Information Disclosure Statement, since it is being submitted prior to the issuance of a first official action on the merits or expiration of the three month period following filing of the above-captioned application.

The above information is presented so that the Patent and Trademark Office can, in the first instance, determine any materiality thereof to the claimed invention. See 37 CFR 1.104(a) and 1.106(b) concerning the PTO duty to consider and use any such information. It is respectfully requested that the information be expressly considered during the prosecution of this application, and that the documents cited in the attached Form PTO-1449 be made of record therein and appear on the first page of any patent to issue therefrom.



The Commissioner is authorized to charge our Deposit Account No. 01-2340 for any fee which is deemed by the Patent and Trademark Office to be required to effect consideration of this statement.

Respectfully submitted,

ARMSTRONG, WESTERMAN, HATTORI, McLELAND & NAUGHTON, LLP

Nicolas E. Seckel Attorney for Applicant(s) Reg. No. 44,373

Atty. Docket No. **001200** 1725 K Street, N.W., Suite 1000 Washington, DC 20006

Tel: (202) 659-2930 Fax: (202) 887-0357

NES/ya

Enclosures: PTO-1449

European Search Report and 5 references